Studies have shown that the spatial distribution and differentiation state of tumor-associated B cells (such as FCRL4+ B cells) and CD8+ T cells in NPC may impact patient prognosis and the effectiveness of immunotherapy9-11. The gene discussed is CD8A; the disease is neoplasm.